Health Trials

About this trial

The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.

Eligibility criteria

Qualifiers

≥18 years of age.

Histologically confirmed, locally advanced, or metastatic solid tumor which has progressed on, or patients intolerant to, all standard therapy, or no standard therapy available, or it is documented that the therapy is refused by the patient.

Measurable disease per RECIST v1.1.

Life expectancy ≥3 months.

Disqualifiers

Any condition that in the opinion of the Investigator would place the patient at an unacceptable risk or cause the patient to be unlikely to fully participate or comply with study procedures.

Received systemic anticancer chemotherapy, targeted agents, antibody therapy for cancer, immunotherapy for cancer, hormonal therapy, or an investigational agent within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study drug treatment.

Major surgery within 3 weeks prior to start of study drug treatment.

Radiation therapy within 4 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study drug treatment). Patients must have recovered from all acute radiotherapy-related toxicities.

Trial design

Treatments tested in this trial

  • JR8603

Treatment groups

94 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.

Locations

2
Harbin Medical University Cancer Hospital150040, HarbinHeiljiang Province, China
Liaoning Cancer Hospital110042, ShenyangLiaoning, China

Sponsors and collaborators

JiaRay Group

Lead sponsor

Source ClinicalTrials.gov